ETON trades 12.7% below Wall Street's consensus target of $72.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ETON achieves its forward estimates and maintains a stable P/E multiple of 58.8x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 17, 2026, Eton Pharmaceuticals, Inc. (ETON) has a Wall Street consensus price target of $72.00, based on estimates from 7 covering analysts. With the stock currently trading at $63.88, this represents a potential upside of +12.7%. The company has a market capitalization of $1.75B.
Analyst price targets range from a low of $68.00 to a high of $78.00, representing a 14% spread in expectations. The median target of $70.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ETON trades at a trailing P/E of 42.6x and forward P/E of 58.8x. Analysts expect EPS to grow -27.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $53.37, with bear and bull scenarios of $33.62 and $70.32 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PRAXPraxis Precision Medicines, Inc. | $8.6B | $310.27 | $611.69 | +97.1% | Buy | — | 18 |
TLRYTilray Brands, Inc. | $312M | $2.34 | $65.01 | +2678.2% | Hold | — | 20 |
MNPRMonopar Therapeutics Inc. | $482M | $71.97 | $126.00 | +75.1% | Buy | — | 14 |
KALAKALA BIO, Inc. | $9468 | $3.83 | $18.25 | +376.5% | Buy | — | 9 |
LNTHLantheus Holdings, Inc. | $6.6B | $101.72 | $102.65 | +0.9% | Buy | 19.0x | 19 |
SUPNSupernus Pharmaceuticals, Inc. | $3.5B | $28.83 | $47.67 | +65.3% | Buy | 10.4x | 12 |
CORTCorcept Therapeutics Incorporated | $7.4B | $69.22 | $132.80 | +91.9% | Buy | 30.6x | 26 |
PAHCPhibro Animal Health Corporation | $1.4B | $35.02 | $28.00 | -20.0% | Buy | 11.4x | 14 |
PRGOPerrigo Company plc | $2.2B | $16.18 | $36.20 | +123.7% | Hold | 7.1x | 36 |
MCKMcKesson Corporation | $129.0B | $1105.04 | $983.13 | -11.0% | Buy | 24.7x | 31 |
Quick answers to the most common questions about buying ETON stock.
Eton Pharmaceuticals, Inc. (ETON) has a consensus 12-month price target of $72, implying 12.7% upside from $63.88. The 7 analysts covering ETON see moderate appreciation potential.
ETON has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $72 implies 12.7% upside from current levels.
At a forward P/E of 58.7727x, ETON trades at a premium valuation. The consensus price target of $72 (12.7% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $78 for ETON, while the most conservative target is $68. The consensus of $72 represents the median expectation. Our quantitative valuation model projects a bull case target of $70 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ETON is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ETON stock forecast based on 7 Wall Street analysts shows a consensus price target of $72, with estimates ranging from $68 (bear case) to $78 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $53, with bear/bull scenarios of $34/$70.
Our quantitative valuation model calculates ETON's fair value at $53 (base case), with a bear case of $34 and bull case of $70. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
ETON trades at a forward P/E ratio of 58.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 42.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on ETON, with a "Buy" consensus rating and $72 price target (12.7% upside). 7 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ETON analyst price targets range from $68 to $78, a 14% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $72 consensus represents the middle ground. Our model's $34-$70 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.